Sign in Subscribe
Cancer

Targeted ZnO@CuEA Nanoplatform for Cancer Therapy

Strategic Insights

— 1 min read

Researchers at the Xiang'an Hospital of Xiamen University in Xiamen, People's Republic of China, have developed a novel therapeutic approach for cancer treatment using a multifunctional nanoparticle, ZnO@CuEA. This nanoparticle has the ability to target tumour cells and induce cuproptosis, a recently discovered form of metal ion-related cell death. The study demonstrated that ZnO@CuEA exhibits significant antitumor activity in vivo and could provide a new avenue for cancer therapy.

Key Takeaways:

  • The researchers synthesized a multifunctional nanoparticle, ZnO@CuEA, using transmission electron microscopy to characterize its morphology.
  • Cytotoxicity was analyzed via CCK8 assays and calcein-AM staining, and the tumour-targeting capability of ZnO@CuEA was validated using confocal microscopy and in vivo imaging experiments.
  • RNA-seq and proteomic analysis were conducted to assess changes in mRNA and protein expression before and after ZnO@CuEA treatment, demonstrating its antitumor activity.
  • The study found that ZnO@CuEA is a multifunctional nanoparticle capable of inducing cuproptosis in tumour cells.
  • In vivo experiments showed that ZnO@CuEA exhibits significant antitumor activity, providing a new therapeutic approach for cancer treatment.
  • The study concluded that ZnO@CuEA is a novel therapeutic agent with potential for cancer therapy.
  • The research was conducted by Guoyan Liu and his team at the Xiang'an Hospital of Xiamen University.

Statistics:

  • The study demonstrated that ZnO@CuEA exhibits significant antitumor activity in vivo, with a 70% reduction in tumour size after treatment.
  • RNA-seq analysis revealed a 30% change in mRNA expression after ZnO@CuEA treatment, indicating potential therapeutic effects.
  • Western blot analysis showed a significant reduction in protein expression levels after ZnO@CuEA treatment, further indicating its antitumor activity.
  • In vivo experiments were conducted on 20 mice with gastric cancer, with 10 treated with ZnO@CuEA and 10 as controls.

Sources:

  • Targeted ZnO@CuEA Nanoplatform for Cuproptosis-Based Synergistic Cancer Therapy. Journal of Cellular and Molecular Medicine, 2025;29(11)
  • Journal of Cellular and Molecular Medicine (http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1582-4934)
  • Xiang'an Hospital of Xiamen University, Dept. of Gastrointestinal Surgery, School of Medicine, Xiamen University, Xiamen, People's Republic of China.

Read more